Tumor Angiogenesis and Novel Vascular Endothelial Receptor (VEGFR)-Specific Small Molecule Inhibitors
- 5 December 2014
- book chapter
- Published by Springer Nature
- p. 245-262
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Combination of antiangiogenesis with chemotherapy for more effective cancer treatmentMolecular Cancer Therapeutics, 2008
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3Clinical Cancer Research, 2008
- Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinomaExpert Opinion on Investigational Drugs, 2008
- Novel Potent Orally Active Selective VEGFR-2 Tyrosine Kinase Inhibitors: Synthesis, Structure−Activity Relationships, and Antitumor Activities of N-Phenyl-N‘-{4-(4-quinolyloxy)phenyl}ureasJournal of Medicinal Chemistry, 2005
- Tumor angiogenesis and accessibility: Role of vascular endothelial growth factorSeminars in Oncology, 2002
- Kallistatin is a new inhibitor of angiogenesis and tumor growthBlood, 2002
- Modeling of loops in protein structuresProtein Science, 2000
- Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with InhibitorsScience, 1997
- Association of Vascular Endothelial Growth Factor Expression with Tumor Angiogenesis and with Early Relapse in Primary Breast CancerJapanese Journal of Cancer Research, 1994
- Vascular Endothelial Growth Factor Is a Secreted Angiogenic MitogenScience, 1989